Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease
progression in patients with cancer. Although it has changed clinical practice, some patients …

The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …

Purpose The AVAGAST study showed that adding bevacizumab to chemotherapy in patients
with advanced gastric cancer improves progression-free survival and tumor response rate …

The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …

Introduction: Ramucirumab (IMC-1121B) is a fully humanized IgG1 monoclonal antibody,
targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I–II trials …

Background Circulating angiogenic factors are altered in patients with mCRC receiving
bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into …

Activated anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases, through gene
fusions, have been found in lung adenocarcinomas and are highly sensitive to selective …

Treatment of metastatic colorectal cancer (mCRC) involves the use of active cytotoxic drugs
(irinotecan, oxaliplatin, 5-fluorouracil [5-FU], and capecitabine) and biological agents …

Therapies targeting tumor angiogenesis are used in a variety of malignancies, however not
all patients benefit from treatment and impact on tumor control may be transient and modest …